ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Palmitoyl Tripeptide-1

Palmitoyl Tripeptide-1

Also known as: Pal-GHK, Biopeptide-CL, Palmitoyl Oligopeptide

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Palmitoyl Tripeptide-1

GHK sequence acts as a matrikine, mimicking collagen degradation fragments. Activates TGF-beta signaling to upregulate collagen gene transcription.

Dosing Information

Half-Life

~3-5 hours (topical bioactivity window)

Typical Dose

2–5 mg

Frequency

Twice daily (topical application)

Cycle Length

Continuous daily use; visible results at 8-12 weeks

Administration Routes:
topical

Benefits

  • Stimulates collagen I and III production in dermal fibroblasts
  • Reduces wrinkle depth and skin roughness
  • Improves skin tone and luminosity
  • Enhances extracellular matrix repair signaling
  • Synergistic with Palmitoyl Tetrapeptide-7 (as Matrixyl 3000)
  • Well-tolerated with minimal irritation potential

Side Effects

Rare mild skin irritationmild
No significant systemic effects due to topical-only usemild

Mechanism of Action

1

GHK sequence acts as a matrikine, mimicking collagen degradation fragments

2

Activates TGF-beta signaling to upregulate collagen gene transcription

3

Palmitoyl group enhances stratum corneum penetration for improved dermal delivery

4

Stimulates fibroblast proliferation and glycosaminoglycan synthesis

5

Synergizes with anti-inflammatory peptides to reduce inflammaging

Contraindications

Do not use this peptide if any of the following apply:

  • Known allergy to any component
  • Severely compromised skin barrier (open wounds, active infections)

Storage & Reconstitution

Unreconstituted (Powder)

Temperature15–25°C (59–77°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature15–25°C (59–77°F)
Duration2-4 weeks

Research Summary

Preclinical

Palmitoyl Tripeptide-1 was developed as a biomimetic signaling peptide based on the naturally occurring GHK sequence. In vitro studies demonstrated significant upregulation of collagen I and III synthesis in human dermal fibroblasts. When combined with Palmitoyl Tetrapeptide-7 (as Matrixyl 3000, developed by Sederma), clinical studies showed synergistic wrinkle reduction superior to either peptide alone. A 12-week study demonstrated up to 44% reduction in wrinkle volume. It is widely incorporated in premium anti-ageing skincare products.

Frequently Asked Questions

Common questions about Palmitoyl Tripeptide-1

UK-Specific Information

Exclusive data points and guidance for UK residents using Palmitoyl Tripeptide-1

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok